Cancer is one of the most complicated illnesses and one of the main causes of death in the world. The fundamental factors include a unique genetic susceptibility, extended exposure to various environmental stressors, and an inadequate diet. When these risk factors are present, genetic changes or mutations accumulate in important proteins inside cells, which speeds up the process of carcinogenesis. The cornerstone of cancer treatment has been traditional chemotherapy. Chemotherapeutic drugs are designed to target cancer cells—which proliferate quickly—as well as certain healthy cells, like the intestinal epithelium. A new class of cancer treatments has arisen in recent years: targeted cancer medications. A precise medical intervention that targets abnormal cells specifically is called targeted therapy. A cell that differs from other cells in certain ways is called an aberrant cell. It might also make use of a normal cellular process, but it would do so excessively, making it entirely dependent on it. Pharmacological medications are used in targeted cancer therapies; these medications, like conventional chemotherapy, slow the growth of the disease, increase cell death, and prevent it from spreading. Targeted cancer therapy falls into two primary categories: small molecule inhibitors and monoclonal antibodies. A medication containing small molecules can enter cells easily and damage their internal structures. They can also be used to disturb molecules that are on the surface of the cell. Larger in size, monoclonal antibodies work extracellularly—that is, outside the cancer cells. They target substances that are either on the surface of cancer cells or very near them. These are produced by cloned cells that produce antibodies that interfere with the particular chemical that is the target. Another use for monoclonal antibodies is the targeted delivery of a cytotoxic agent straight into a cancerous cell.
Keywords: Carcinogenesis, genetic susceptibility, genetic changes, proliferate, monoclonal antibodies, cytotoxic agent.
